In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Steady Year For The Top Tier In Pharma Ahead Of Major Upheaval

Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.

BioPharmaceutical Financing Market Intelligence

Leading Medtechs See Organic Growth Across A Market In Flux

In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.

Financing Outlook 2020 Business Strategies

Scrip 100 Numbers Crunched

The Scrip 100 universe gathers FY2018 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales.

Download PDF

The full Scrip 100 data set for 2020 is now available and includes data on R&D spending, total revenues, employee numbers and sales for the top 100 biopharmaceutical companies (based on FY 2018).

If you are a subscriber, click here to download the data in Excel format.

UsernamePublicRestriction

Register